Warden Bio
2021
Kishnani Kunal
Kishnani Priya, Aravind Asokan, Sun Baodong
Warden Bio is developing novel AAV-mediated gene therapies for glycogen storage disorders (GSDs). The GSD gene therapy is based on research led by the lab of Dr. Priya Kishnani, Chen Family Distinguished Professor & Division Chief for Medical Genetics at Duke University, in close collaboration with Dr. Aravind Asokan, Professor & Director of Gene Therapy at Duke University and Co-Founder of StrideBio. Over the past three decades, Dr. Kishnani has built an interdisciplinary team with world-leading GSD expertise whose efforts are most notably demonstrated by the long-standing research and clinical experience that resulted in FDA approval of alglucosidase alfa (Myozyme/Lumizyme) as the first available treatments for Pompe disease.
Warden Bio was acquired by Kriya Therapeutics in January 2022.
Success Story
Kriya Expands Gene Therapy Pipeline and Establishes its Rare Disease Therapeutic Area Division with the Acquisition of Warden Bio
REDWOOD CITY, Calif. and RESEARCH TRIANGLE PARK, N.C., — January 7, 2022 — Kriya Therapeutics, Inc., a fully integrated company pioneering novel technologies and therapeutics in gene therapy, announced today that it has acquired Warden Bio, a company developing novel AAV-mediated gene therapies for glycogen storage disorders (GSDs).